Leukocytosis and alteration of hemoglobin level in patients with severe COVID-19: Association of leukocytosis with mortality

Babak Sayad1 | Zeinab Mohseni Afshar1 | Feizollah Mansouri1 | Zohreh Rahimi2,3

1Infectious Diseases Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
3Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence
Zohreh Rahimi, Clinical Biochemistry, Medical School, P.O.Box: 67148-69914, Daneshgah Avenue, Kermanshah, Iran.
Email: zrahimi@kums.ac.ir; rahimizus@yahoo.com

Dear Editors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). The clinical characteristics of COVID-19 pandemic announced by the World Health Organization (WHO) in March 20201 may be presented by a severe form of pneumonia in some patients (10%-15%) which might progress toward acute respiratory distress syndrome, multi-organ failure and death.2 The clinical laboratory provides important information related to the COVID-19 diagnosis, prognosis, and response to therapy.3 In severely affected patients with COVID-19, leukocytosis was more prevalent as it was observed in 11.4% severe COVID-19 patients compared to 4.8% in patients with mild to moderate disease.3

For the first time we report white blood cells (WBCs) count and hemoglobin (Hb) level among patients with severe COVID-19 from Iran (Table 1). The Farabi Hospital of Kermanshah University of Medical Sciences, Kermanshah, Iran as the second referral center of COVID-19 in Kermanshah Province, with a population around 2,000,000, started the admission of COVID-19 patients from March 7, 2020. A total number of 3,574 individuals referred to the emergency unit of this hospital from March 7 to May 12, 2020 that among them 537 individuals were hospitalized due to COVID-19 infection according to the chest CT scan and/or real time polymerase chain reaction. Seventy-four severely affected patients (44 males and 30 females) were admitted to the intensive care unit (ICU) of the hospital. The mean age of all ICU admitted patients was 65.1 ± 17.1 years (23-90 years), with the mean age of 61.4 ± 18.5 years (23-90 years) in men and the mean age of 70.5 ± 13.2 years (39-89 years) in women (Table 1).

Among all severely affected patients the mean WBCs count was 9.1 ± 4.9 × 10^9/L (8.9 ± 4.9 × 10^9/L in males and 9.4 ± 5.0 × 10^9/L in females). In survivors the WBCs count was 7.6 ± 3.5 × 10^9/L compared to 10.5 ± 5.6 × 10^9/L (P = .008) in non-survivors. Comparing survivors with non-survivors indicated among non-survivors 16 out of 39 patients (41%) had WBCs count upper normal range (>11 × 10^9/L). However, only 4 out of 35 (11.4%) survived patients had WBCs count more than 11 × 10^9/L (χ^2 = 8.2, P = .004, OR = 1.16 (CI 1.03-1.3, P = .015). Also, the WBCs count was 10.5 ± 6.0 × 10^9/L in patients required intubation compared to 8.3 ± 4.1 × 10^9/L (P = .098) in those patients did not require intubation. Furthermore, higher WBCs count was detected in patients with comorbidities (hypertension, diabetes mellitus, coronary artery disease, cancer, renal transplantation, chronic obstructive pulmonary disease, and osteomyelitis) than those without comorbidities (9.5 ± 4.9 vs 8.2 ± 4.8 × 10^9/L, P = .27; Table 1). There were seven patients with leukopenia (1-3.8 × 10^9/L) that four of them (57.1%) died.

The mean level of Hb was 140.2 ± 24.3 g/L (75-205 g/L) in all patients. In men the mean level of Hb was 143.1 ± 23.5 g/L (75-205 g/L) and in women was 136.1 ± 25.3 g/L (98-200 g/L). The mean Hb level in 35 survived patients was 141.1 ± 25.8 g/L (P = .75). There were 51 patients (68.9%) with comorbidities and the mean Hb level of 141.4 ± 26.4 g/L compared to 23 patients (31.1%) without comorbidities and the Hb level 137.6 ± 19.3 g/L (P = .49). Among patients 26 out of 74 (35.1%) required tracheal intubation with the mean Hb level 137.3 ± 23.2 g/L compared to the mean level of 141.8 ± 25.1 g/L in 48 patients who did not require intubation (P = .44; chi-square = 5.5, P = .019).
There were 12 patients with low level of Hb (75-115 g/L) that 5 of them (41.7%) died. Thirteen (59.1%) out of 22 patients with high levels of Hb (150-205 g/L) died. Among studied patients only there was a severely anemic man (Hb 75 g/L) who required tracheal intubation that died after 3 days hospitalization. Among 40 patients with the normal Hb levels (116-148 g/L) the rate of death was 52.5% (21 out of 40). There were 50 patients <60 years with WBCs count 8.8 ± 4.7 $\times 10^9$/μL compared to 9.1 ± 4.9 $\times 10^9$/μL in patients ≥60 years ($P = .81$). The Hb level in patients <60 years was 148 ± 22.6 g/L compared to 136.8 ± 24.7 g/L in patients ≥60 years ($P = .059$).

Related to the alteration of Hb level in patients infected with SARS-CoV-2 there are few studies that were subjected a meta-analysis. In three out of four studies, the Hb level in severe COVID-19 patients was significantly lower than those with milder forms. The meta-analysis, included 1210 COVID-19 patients that among them 224 were with severe disease (18.5%), suggested that in severe COVID-19 patients compared to milder forms of the disease, Hb levels essentially decreased that needs clinical studies to investigate the effectiveness of blood transfusion support in prevention of progression to severe disease and death. Also, in a study consisted of nine severe ICU admitted Chinese patients with COVID-19 the lower level of Hb [112 g/L (106-130.5 g/L)] was detected compared to 134.5 g/L (114.8-144 g/L) ($P = .054$).

However, an artificial intelligence framework that has been developed according to dataset from 53 hospitalized patients (case series) in two hospitals from China predicted the clinical severity of COVID-19. In their model, higher Hb levels were associated with poorer outcomes. According to this predictive model mild increased to moderate level of Hb [112 g/L (106-130.5 g/L)] was detected compared to 114.5 g/L (111.8-144 g/L) ($R^2 = .054$).

CONFLICT OF INTEREST

The authors declare they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Visualization, Writing-Review and Editing: Babak Sayad
Methodology and Formal Analysis: Zeinab Mohseni Afshar
Investigation and Editing: Feizollah Mansouri
Validation and Writing-Original Draft Preparation: Zohreh Rahimi

Table 1. Age, hemoglobin (Hb) level, and white blood cells (WBCs) count in severe patients with COVID-19

| Variable | All patients n = 74 | Survivors (n = 35) | Non-survivors (n = 39) | Patients did not require intubation n = 48 | Patients required intubation n = 26 | Patients without comorbidities (n = 23) | Patients with comorbidities (n = 51) |
|----------|---------------------|-------------------|-----------------------|-------------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|
| Age (Years) | Males (n = 44) | 65.1 ± 17.1 (23-90) | 63.6 ± 18.7 | 66.5 ± 15.5 (75-150) | 63.7 ± 18.8 | 67.9 ± 12.8 (116-170) | 69.4 ± 15.8 (75-150) |
| | Female (n = 30) | 70.5 ± 13.2 (39-89) | 71.8 ± 14.6 | 69.3 ± 12.4 (75-160) | 73 ± 13.8 | 67.2 ± 12.3 (116-170) | 61.8 ± 18 (75-150) |
| WBCs ×$10^9$/μL | Males | 9.1 ± 4.9 (1-24.8) | 7.6 ± 3.5 | 10.5 ± 5.6 (75-160) | 8.2 ± 4.1 | 10.5 ± 6.0 (116-170) | 8.2 ± 4.8 |
| | Females | 8.9 ± 4.9 (1-23.7) | 7.7 ± 4 | 10.1 ± 5.4 (75-160) | 8.6 ± 4.7 | 9.7 ± 5.4 (116-170) | 8.7 ± 5 |
| Hb (g/L) | Males | 140.2 ± 24.3 (75-205) | 139.3 ± 22.9 | 141.1 ± 25.8 (75-205) | 141.8 ± 25.1 | 137.3 ± 23.0 (75-205) | 137.6 ± 23.0 (75-205) |
| | Females | 143.1 ± 23.5 (75-205) | 141.4 ± 21.1 | 144.8 ± 25.9 (75-205) | 146.5 ± 26.4 | 137.2 ± 20.3 (75-205) | 142 ± 16.4 |
| | Patients without comorbidities (n = 23) | 134.8 ± 25.9 (75-205) | 135.9 ± 25.8 (75-205) | 141.8 ± 25.1 | 135 ± 25 | 137.5 ± 26.0 (75-205) | 125.3 ± 23.1 |
| | Patients with comorbidities (n = 51) | 141.8 ± 25.8 (75-205) | 141.1 ± 25.8 (75-205) | 141.8 ± 25.1 | 135 ± 25 | 137.5 ± 26.0 (75-205) | 138 ± 25.6 (75-205) |

Note: SD = standard deviation, $P = .059$.
All authors have read and approved the final version of the manuscript.

Zohreh Rahimi (corresponding author) had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

ETHICS STATEMENT
Although our study was an observational study, verbal consent was obtained from patients or from the next-of-kin. The Ethics Committee of Kermanshah University of Medical Sciences approved the study (Ethics code: IR.KUMS.REC.1399.049) and the study was in accordance with the principles of the Declaration of Helsinki II.

ORCID
Babak Sayad https://orcid.org/0000-0001-8686-9986
Zohreh Rahimi https://orcid.org/0000-0001-7589-3307

REFERENCES
1. Touyz RM, LI H, Delles C. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci. 2020;134:747-750.
2. Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther. 2020;42(2):116-117.
3. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol. 2020;42(Suppl 1):11-18.
4. Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta. 2020;507:174-180.
5. Jiang X, Coffee M, Bari A, et al. Towards an artificial intelligence framework for data-driven prediction of coronavirus clinical severity. Comput Mater Continua. 2020;63(1):537-551.

How to cite this article: Sayad B, Afshar ZM, Mansouri F, Rahimi Z. Leukocytosis and alteration of hemoglobin level in patients with severe COVID-19: Association of leukocytosis with mortality. Health Sci Rep. 2020;3:e194. https://doi.org/10.1002/hsr2.194